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▼The tumor suppressor genes p53 and p16 (MTS1,
CDKN2), which function as negative regulators in cell cycle
control, exhibit the highest mutation rates found so far in
human cancers (Ref. 1, 2). Mutations in these genes seem to
have a prognostic value with regard to tumor progression
(Ref. 3, 4). Many tumors harbor concomitant mutations in
both genes (Ref. 5, 6), suggesting that p53 and p16 oper-
ate in different pathways, each of which is important in
suppressing malignant transformation. In contrast to p53,
which is mainly altered by missense mutations (Ref. 1),
p16 is most frequently inactivated by homozygous dele-
tions (Ref. 7, 8).
Detection of homozygous deletions of p16 via conven-
tional single-strand conformation polymorphism analysis
of PCR products (SSCP-PCR analysis) in primary tumors
usually fails; contamination of tumors with normal cell
fractions originating from surrounding tissue, blood vessels,
or infiltrating lymphocytes frequently results in amplifica-
tion signals which then are misinterpreted as non-mutated
tumor DNA.
We have developed a combined screening system −
comparative multiplex PCR (CMP-PCR) analysis followed
by non-radioactive SSCP/HET-PCR analysis with nested
primers−which enables us to detect homozygous deletions
in p16 (Figures 1 and 4) in addition to point mutations in
p53 (Figures 2 and 3). Furthermore, loss of heterozygos-
ity (LOH), micro-deletions/insertions, and point mutations
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can be detected simultaneously in both genes (p16 exons
1−3, p53 exons 5−8).
Our comparative multiplex analysis is based on three
distinct CMP-PCR assays (Table 1, a−c), each containing
two p53 and two p16 specific primers. The three assays
can be managed in parallel in a single PCR run. The CMP-
PCR products are used as templates in the subsequent
SSCP/HET-PCR (Table 2, a−g), which is based on seven
different PCR assays (one for every exon analyzed), with
one nested primer included in each, in order to achieve
high-quality amplicons without nonspecific side products
for subsequent SSCP/HET analysis. Again, the seven assays
can be managed in parallel in a single PCR run.
All PCR reactions are performed, following a standard
protocol (Ref. 9), in a reaction volume of 100 µl containing
50 mM KCl, 10 mM Tris-HCl (pH 8.4 at room temperature),
1.5mMMgCl2, 100µg/µl gelatin, 200µMof each deoxynu-
cleotide triphosphate (dATP, dCTP, dGTP, dTTP), 300 ng of
each primer (Table 1, 2) and 2.5 units of Taq polymerase,
and using a DNA thermal cycler (Perkin Elmer, TC1).
CMP-PCR (Table 1)
DNA samples (500 ng) are denatured for 5 min at 95◦C,
incubated for 32 cycles (3 cycles: 1 min at 95◦C, 1 min at
62◦C, 1 min at 72◦C; 3 cycles: 1 min at 95◦C, 1 min at 61◦C,
1 min at 72◦C; 3 cycles: 1 min at 95◦C, 1 min at 60◦C, 1 min
at 72 ◦C; 3 cycles: 1 min at 95◦C, 1 min at 58◦C, 1 min at
72◦C; 20 cycles: 1min at 95◦C, 1min at 56◦C, 1min at 72◦C)
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Table 2. SSCP/HET-PCR
(a) SSCP/HET-PCR 1 (p16 Exon 1)
1bP16E1 5′ TGCGG AGAGG GGGAG AGCAG 3′ Template 1P16E1−2P16E1 = 351 bp
2P16E1 5′ GCGCT ACCTG ATTCC AATTC 3′ 1bP16E1 (nested)−2P16E1 = 278 bp
SmaI 106 bp + 172 bp (optional)
(b) SSCP/HET-PCR 2 (p16 Exon 2)
1bP16E2 5′ TGGCT CTGAC CATTC TGTTC 3′ Template 1P16E2−2bP16E2 = 515 bp
2bP16E2 5′ GAATG CTCTG AGCTT TGGAA 3′ 1bP16E2 (nested)−2bP16E2 = 395 bp
SmaI 139 bp + 256 bp (optional)
(c) SSCP/HET-PCR 3 (p16 Exon 3)
1bP16E3 5′ GAGAG GAGGG CGGGA TGTGC 3′ Template 1P16E3−2P16E3 = 195 bp
2P16E3 5′ GACCT TCGGT GACTG ATGAT 3′ 1bP16E3 (nested)−2P16E3 = 147 bp
(d) SSCP/HET-PCR 4 (p53 Exon 5)
1P53E5 5′ TTCCT CTTCC TGCAG TACTC 3′ Template 1P53E5−2P53E6 = 408 bp
2P53E5 5′ ACCCT GGGCA ACCAG CCCTG T 3′ 1P53E5−2P53E5 (nested) = 245 bp
(e) SSCP/HET-PCR 5 (p53 Exon 6)
1P53E6 5′ACAGG GCTGG TTGCC CAGGG T 3′ Template 1P53E5−2P53E6 = 408 bp
2P53E6 5′ AGTTG CAAAC CAGAC CTCAG 3′ 1P53E6 (nested)−2P53E6 = 184 bp
(f) SSCP/HET-PCR 6 (p53 Exon 7)
1P53E7 5′ GTGTT GTCTC CTAGG TTGGC 3′ Template 1P53E7−2P53E7 = 188 bp
3P53E7 5′ AAGCA GAGGC TGGGG CACAG 3′ 1P53E7−3P53E7 (nested) = 179 bp
(g) SSCP/HET-PCR 7 (p53 Exon 8)
1P53E8 5′ TATCC TGAGT AGTGG TAATC 3′ Template 1P53E8−2P53E8 = 213 bp
3P53E8 5′ AATCT GAGGC ATAAC TGCAC 3′ 1P53E8−3P53E8 (nested) = 208 bp
and finally extended for 5 min at 72◦C. Ten microlitres of
the CMP-PCR product are analyzed by gel electrophoresis
on a 2% agarose gel and visualized by ethidium bromide
fluorescence.
SSCP/HET-PCR (Table 2)
The bands are excised and incubated separately for 12 h
at 4◦C in 500 µl sterile distilled water. After mixing and
brief centrifugation, 10 µl of this solution serves as a tem-
plate for the second amplification round with the nested
primers under otherwise identical PCR conditions. Ten mi-
crolitres of the SSCP/HET-PCR products again are analysed
by gel electrophoresis on a 2% agarose gel and visualized
by ethidium bromide fluorescence.
For SSCP/HET analysis, 4 µl of the SSCP/HET-PCR prod-
uct aremixedwith 4µl of SSCP-buffer (2mMEDTA, 0.005%
Table 1. CMP-PCR
(a) CMP-PCR 1 (p16 Exon 1 + p53 Exon 7)
1P16E1 5′ CAGCA CCGGA GGAAG AAAG 3′ 1P16E P16E1 = 351 bp
2P16E1 5′ GCGCT ACCTG ATTCC AATTC 3′
1P53E7 5′ GTGTT GTCTC CTAGG TTGGC 3′ 1P53E7−2P53E7 = 188 bp
2P53E7 5′ GTCAG AGGCA AGCAG AGGCT 3′
(b) CMP-PCR 2 (p16 Exon 2 + p53 Exon 8)
1P16E2 5′ GGAAA TTGGA AACTG GAAGC 3′ 1P16E2−2bP16E2 = 515 bp
2bP16E2 5′ GAATG CTCTG AGCTT TGGAA 3′
1P53E8 5′ TATCC TGAGT AGTGG TAATC 3′ 1P53E8−2P53E8 = 213 bp
2P53E8 5′ AAGTG AATCT GAGGC ATAAC 3′
(c) CMP-PCR 3 (p16 Exon 3 + p53 Exons 5+6)
1P16E3 5′ TTGCG AGAAC TTTAT CCATA 3′ 1P16E3−2P16E3 = 195 bp
2P16E3 5′ GACCT TCGGT GACTG ATGAT 3′
1P53E5 5′ TTCCT CTTCC TGCAG TACTC 3′ 1P53E5−2P53E6 = 408 bp
2P53E6 5′ AGTTG CAAAC CAGAC CTCAG 3′
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FIGURE 1. CMP-PCR analysis (CMP-PCR 1−3, Table 1) of a
congenital nevus (N) and a melanoma cell line [MRI-H-221 (M)]. All
p16-specific bands, corresponding to exon 1 (351 bp), exon 2 (515 bp)
and exon 3 (195 bp), are present in the congenital nevus but clearly
absent in MRI-H-221. By contrast, all p53-specific bands are present at
similar intensities in both lesions. The homozygous deletion of p16 in
MRI-H-221 is independently verified by CMP-PCR 1, 2 and 3. We also
found homozygous deletion of p16 by CMP-PCR analysis (all
p16-specific bands were clearly absent) in two primary melanomas (data
not shown). Outside lanes contain 7 µl (70 ng) of a 100 bp ladder as
size marker.
bromophenol blue, 0.005% xylene cyanol in deionized
formamide) and incubated in the TC1 for 10 min at 98◦C
prior to cooling for 10 min on an ice bath. Samples are
applied to a commercial 10% polyacrylamide gel [Clean
Gel (Pharmacia)] on a horizontal electrophoresis cham-
ber [Multiphor II (Pharmacia)] at 15◦C and 4◦C using
the PCR Fragment Analysis Kit (Pharmacia). Electrophore-
sis and silver staining is performed as described by the
manufacturer.
We consider our combined system to be a valuable tool
for simultaneous mutation screening in p53 and p16.
FIGURE 2. SSCP/HET analysis of exon 5 of the p53 gene
(SSCP/HET-PCR, Table 2 d) from six melanoma cell lines. The
silver-stained gel shows a point mutation by three aberrant single-strand
bands in lane 3, corresponding to cell line MRI-H-221. The
double-stranded band, inherent in the system (indicated by an arrow)
could be useful for the identification of single-base-pair deletions (HET
analysis).
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FIGURE 3. DNA sequence analysis of the melanoma cell line
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FIGURE 4. Modified CMP-PCR 1 assay. In order to find out if it is
possible to detect a homozygous deletion of p16 in tumors even when
the tumor DNA is contaminated by some wild-type tissue, we added an
increasing amount of the congenital nevus DNA to the cell line DNA,
using the CMP-PCR1 approach. No p16 band is visible with an
admixture of 1% congenital nevus DNA, a p16 band is just visible at 3%,
very faint p16 bands are seen with up 10% and up to 25% bands are
clearly distinguishable from the p16 band of pure congenital nevus DNA
(N). Note that homozygous deletion should be verified by Southern
blotting in cases of ambiguous results (e.g. faint p16 bands).
Products Used
DNA thermal cycler 480: DNA thermal cycler 480
from PE Applied Biosystems
DNA thermal cycler 480: DNA thermal cycler 480
from PE Applied Biosystems
Thermal Cycler: Thermal Cycler from Techne
(Cambridge) Ltd
thermal cycler: thermal cycler from MJ Research
Inc
CleanGel: CleanGel from Pharmacia
Multiphor II: Multiphor II from Pharmacia
PCR Fragment Analysis Kit: PCR Fragment Anal-
ysis Kit from Pharmacia
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